Strong On High Volume: XOMA (XOMA)

Trade-Ideas LLC identified XOMA (XOMA) as a strong on high relative volume candidate
By TheStreet Wire ,

Trade-Ideas LLC identified

XOMA

(

XOMA

) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified XOMA as such a stock due to the following factors:

  • XOMA has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $15.5 million.
  • XOMA has traded 1.4 million shares today.
  • XOMA is trading at 2.27 times the normal volume for the stock at this time of day.
  • XOMA is trading at a new high 9.76% above yesterday's close.

'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in XOMA with the Ticky from Trade-Ideas. See the FREE profile for XOMA NOW at Trade-Ideas

More details on XOMA:

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. Currently there is 1 analyst that rates XOMA a buy, no analysts rate it a sell, and 5 rate it a hold.

The average volume for XOMA has been 4.4 million shares per day over the past 30 days. XOMA has a market cap of $207.5 million and is part of the health care sector and drugs industry. The stock has a beta of 2.96 and a short float of 24.9% with 1.80 days to cover. Shares are down 65.7% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates XOMA as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and generally disappointing historical performance in the stock itself.

Highlights from the ratings report include:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 99.7% when compared to the same quarter one year ago, falling from -$11.90 million to -$23.76 million.
  • Looking at the price performance of XOMA's shares over the past 12 months, there is not much good news to report: the stock is down 56.25%, and it has underformed the S&P 500 Index. In addition, the company's earnings per share are lower today than the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • XOMA, with its very weak revenue results, has greatly underperformed against the industry average of 11.3%. Since the same quarter one year prior, revenues plummeted by 57.5%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.
  • XOMA CORP's earnings per share declined by 17.6% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, XOMA CORP continued to lose money by earning -$0.67 versus -$1.40 in the prior year. This year, the market expects an improvement in earnings (-$0.57 versus -$0.67).
  • Net operating cash flow has slightly increased to -$16.35 million or 3.26% when compared to the same quarter last year. In addition, XOMA CORP has also vastly surpassed the industry average cash flow growth rate of -46.79%.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...